Online inquiry

IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2140MR)

This product GTTS-WQ2140MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2140MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8031MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ8324MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ11329MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ15046MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ13870MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ5230MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ8418MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ9236MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW